The IncRNA PCAT29 Inhibits Oncogenic Phenotypes in Prostate Cancer

Rohit Malik1,2, Lalit Patel1,2, John R. Prensner1,2, Yang Shi1,3, Matthew K. Iyer1,2, Shruthi Subramaniyan1, Alexander Carley1, Yashar S. Niknafs1,2, Anirban Sahu1,2, Sumin Han1,4, Teng Ma1,4, Meilan Liu4, Irfan A. Asangani1,2, Xiaojun Jing1,2, Xuhong Cao1,2, Saravana M. Dhanasekaran1,2, Dan R. Robinson1,2, Felix Y. Feng1,4,5, and Arul M. Chinnaiyan1,2,5,6

Abstract

Long noncoding RNAs (IncRNA) have recently been associated with the development and progression of a variety of human cancers. However, to date, the interplay between known oncogenic or tumor-suppressive events and IncRNAs has not been well described. Here, the novel IncRNA, prostate cancer–associated transcript 29 (PCAT29), is characterized along with its relationship to the androgen receptor. PCAT29 is suppressed by DHT and upregulated upon castration therapy in a prostate cancer xenograft model. PCAT29 knockdown significantly increased proliferation and migration of prostate cancer cells, whereas PCAT29 overexpression conferred the opposite effect and suppressed growth and metastases of prostate tumors in chick chorioallantoic membrane assays. Finally, in prostate cancer patient specimens, low PCAT29 expression correlated with poor prognostic outcomes. Taken together, these data expose PCAT29 as an androgen-regulated tumor suppressor in prostate cancer.

Implications: This study identifies PCAT29 as the first androgen receptor–repressed IncRNA that functions as a tumor suppressor and that its loss may identify a subset of patients at higher risk for disease recurrence.

Visual Overview: http://mcr.aacrjournals.org/content/early/2014/07/31/1541-7786.MCR-14-0257/F1.large.jpg.

Mol Cancer Res; 12(8); 1081–7. © 2014 AACR.
Materials and Methods

Cell lines and reagents
Prostate cancer cells were cultured as follows: VCaP cells in DMEM with GlutaMAX (Invitrogen) and LNCaP and DU145 cells in RPMI-1640 (Invitrogen) in a 5% CO2 culture incubator. All the media were supplemented with 10% FBS (Invitrogen) and 1% penicillin–streptomycin (Invitrogen). All cell lines were purchased from ATCC and were authenticated.

For stable knockdown of PCAT29, LNCaP and VCaP cells were transfected with lentiviral constructs encoding 2 different PCAT29 shRNAs or nontargeting shRNAs in the presence of polybrene (8 μg/mL; Supplementary Table S1A). After 48 hours, transduced cells were grown in culture media containing 3 to 5 μg/mL puromycin. For PCAT29 overexpression, 2 isoforms of PCAT29 were generated by subcloning the PCR product into the CPOI sites of the pCDH-CMV vector (System Biosciences). Five hundred base pairs of the genomic region was attached at the 5’ end of each isoform. Lentiviral particles were made and DU145 cells were transduced as described above.

Gene expression by quantitative PCR
Total RNA was isolated using TRIzol (Invitrogen) and an RNeasy kit (Qiagen) according to manufacturers’ instruction. Total RNA was reverse transcribed into cDNA using SuperScript III and random primers (Invitrogen). Quantitative PCR (qPCR) was performed using SYBR Green Master Mix (Applied Biosystems) on an Applied Biosystems 7900HT Real-Time System. The relative quantity of the target gene was computed for each sample using the ΔΔ Ct method by comparing mean Ct of the gene to the mean Ct of the housekeeping gene GAPDH. All the primers were obtained from Integrated DNA Technologies (IDT). Sequences of all the primers used are listed in Supplementary Table S1B.

Rapid amplification of cDNA ends
5’ and 3’ RACE was performed using the GeneRacer RLM-RACE kit (Invitrogen) following manufacturer’s instruction. RACE PCR products were separated on a 1% agarose gel. Individual bands were gel purified, cloned in pcR4-TOPO vector, and sequenced using M13 primers.

Expression of PCAT29 after castration in prostate tumor xenograft model
Five-week-old male nude athymic BALB/c nu/nu mice (Charles River Laboratory) were used for xenograft studies. LNCaP cells were resuspended in 100 μL of PBS with 20% Matrigel (BD Biosciences) and implanted subcutaneously into the left flank regions of the mice. Mice were castrated and euthanized 5 days after castration. RNA was extracted from the xenografts and expression of PCAT29 and FKBP5 was measured. All experimental procedures involving mice were approved by the University Committee on Use and Care of Animals at the University of Michigan (Ann Arbor, MI) and conform to their relevant regulatory standards.

Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed with polyclonal androgen receptor antibody (Millipore PG21) using HiCell ChIP kit (Diagenode) following manufacturer’s instruction. Briefly, cells were treated with 10 μmol/L MDV3100 or 10 μmol/L bicalutamide 16 hours before the treatment with 10 nmol/L DHT for 12 hours. Approximately 1 million cells were cross-linked per antibody with 1% formaldehyde. Chromatin was sonicated to an average length of 500 bp and centrifuged to remove debris. Magnetic protein-G beads were coated with 6 μg of antibody and incubated with chromatin overnight at 4°C. Protein–chromatin–antibody complexes were washed thrice and cross-linking was reversed. ChIP products were cleaned using IPure kit (Diagenode). Eluted DNA was quantified by RT-PCR using primers described in Supplementary Table S1B.

Cell proliferation and migration assay
LNCaP and DU145 cells stably expressing PCAT29 shRNA-1 and 2 or PCAT29 isoform 1 and 2 were seeded in 24-well plates. Cells were trypsinized and counted by using Coulter Counter (Beckman Coulter) at the indicated time points in triplicate. For migration assays, approximately 1 × 105 cells were seeded in the upper chamber of a Boyden chamber. About 500 μL of complete medium (10% FBS) was added to the lower chamber as a chemoattractant. Forty-eight hours after seeding, cells on the upper surface were removed using a cotton swab. Inserts were fixed with 3,7% formaldehyde and migrated cells on the lower surface of the membrane were stained with crystal violet. The inserts were treated with 10% acetic acid, and absorbance was measured at 560 nm.

Gene expression microarray
Expression profiling of VCaP and LNCaP cells after PCAT29 knockdown was performed using the Agilent Whole Human Genome Oligo Microarray as described (7). GEO accession number: GSE58397.

Chicken chorioallantoic membrane assay
22RV1 cells were transduced with empty vector (pcDH) or PCAT29 isoform-1. A total of 105 cells were inoculated on the chicken chorioallantoic membrane (CAM) assay as described previously (10). For tumor growth and metastasis, the eggs were incubated for 18 days in total, after which the extra-embryonic tumor were exercised and weighed, and the embryonic livers were harvested and analyzed for the presence of tumor cells by quantitative human Alu-specific PCR. Quantification of human cells in the extracted DNA was performed as described (11). Fluorogenic TaqMan qPCR probes were applied as above and DNA copy numbers were quantified.

Kaplan–Meier analysis of PCAT29
For outcomes analysis, PCAT29 expression was determined on a cohort of 51 radical prostatectomy specimens from patients with prostate cancer at the University of Michigan (Ann Arbor, MI) and was correlated with survival in patients with prostate cancer.
As shown in a genome browser view, cDNA ends (RACE) to determine the full exon structure. PCAT29 gene spans over a 10-kb stretch (Fig. 1A; Supplementary Fig. S1A). PCAT29 is composed of 6 exons that are alternatively spliced to produce multiple isoforms (Fig. 1B). To further characterize PCAT29, we interrogated recently published ENCODE data for H3K4 trimethylation (H3K4me3) and DNaseI hypersensitive sites (DNaseH), marks that predicts for open chromatin state and are commonly found near or at the TSSs, generated in the prostate cancer cell line LNCaP (4). We found several DNaseH and H3K4 trimethylation peaks at the TSS of PCAT29, suggesting that PCAT29 is an actively transcribed gene (Fig. 1A).

To confirm that PCAT29 is indeed a noncoding RNA, we assessed the protein-coding potential of PCAT29 using the coding potential calculator (CPC) algorithm, which discriminates coding genes (positive score) from noncoding transcripts (negative score; ref. 12). PCAT29 had a CPC score of −0.8921, whereas protein-coding genes such as TP53 and β-actin scored +8.25 and +3.70, respectively (Supplementary Fig. S1B). Consistent with this finding, we found that in both LNCaP and VCaP cells, expression of PCAT29 was limited to nucleus, whereas other protein-coding mRNAs, such as GAPDH and β-actin, were expressed in cytoplasm (Fig. 1C). We then verified the expression of PCAT29 in various prostate cancer cell lines (LNCaP, VCaP, 22RV1, DU145, PC3) and immortalized or primary prostate epithelial cells (RPWE and PrEC). PCAT29 expression was highest in androgen receptor–dependent cell lines such as LNCaP, VCaP, and 22RV1 (Supplementary Fig. S1C).

**Results**

**PCAT29 is a novel long nuclear noncoding RNA**

Using RNA-Seq data from prostate cancer tissues, we previously identified 121 IncRNAs, named PCATs, which demonstrate differential expression or outlier profiles in prostate cancer compared with normal tissue (3). Here we characterize and functionally investigate one of the top outlier IncRNAs, PCAT29 (Ensembl ID ENSG00000259641). Using the predicted transcript structures, we designed exon spanning primers and performed rapid amplification of cDNA ends (RACE) to determine the full exon structure. As shown in a genome browser view, PCAT29 is a 694-bp polyadenylated transcript present on chr15(q23), and the PCAT29 gene spans over a 10-kb stretch (Fig. 1A; Supplementary Fig. S1A).
Next, we assessed the expression of PCAT29 in various tissues using transcriptome sequencing data. PCAT29 expression, although not limited to prostate, was enriched in prostate samples compared with other tissues (Supplementary Fig. S1D).

Androgen receptor binds to the PCAT29 promoter and regulates PCAT29 expression

We next examined the effect of androgen receptor signaling on PCAT29 in LNCaP cells stimulated with 10 nmol/L DHT. As shown in Fig. 2A, PCAT29 expression was suppressed upon stimulation with DHT in a time-dependent fashion both in LNCaP and VCaP cells. In contrast, expression of canonical androgen receptor target genes, such as FKBP5 and KLK3, was increased upon stimulation (Supplementary Fig. S2A). To examine whether the suppression of PCAT29 was androgen receptor–specific, LNCaP cells were pretreated with the androgen receptor antagonists MDV3100 or bicalutamide before treatment with DHT. As expected, DHT stimulation suppressed the expression of PCAT29, and pretreatment with MDV3100 or bicalutamide rescued this suppression. Similarly, expression of PCAT29 in LNCaP cells grown in charcoal-stripped media as well as in an androgen receptor–independent variant of LNCaP cells (C42) was higher than in cells grown in serum-containing media and LNCaP cells, respectively (Supplementary Fig. S2B and S2C). We next investigated whether androgen receptor suppresses the expression of PCAT29 in vivo. LNCaP xenografts were established in mice followed by physical castration to ablate androgen receptor signaling. As expected, 5 days of castration led to significant increase in the expression of PCAT29 in tumors (Fig. 2C). In contrast, expression of FKBP5 was reduced in tumors from castrated mice. Taken together, our results suggest that stimulation

![Figure 2](image-url)
of androgen receptor leads to suppression of PCAT29 expression.

To further study the association of PCAT29 expression with androgen signaling, we interrogated published ChIP-Seq data (13) and found androgen receptor–binding sites in the promoter region of PCAT29 (Fig. 2D). These peaks were similar to those observed in other known androgen receptor–regulated genes (Supplementary Fig. S2D). Upon closer inspection, we found a canonical androgen receptor–binding site near the PCAT29 TSS in a putative enhancer region bounder by androgen receptor (Fig. 2D). We confirmed our ChIP-Seq data by performing ChIP for androgen receptor followed by PCR for the PCAT29 promoter. As shown in Fig. 2D, stimulation of VCaP cells with DHT led to an increase in association of androgen receptor with the PCAT29 promoter. This association was reduced in cells pretreated with bicalutamide and MDV3100. Taken together, our data suggest that androgen receptor can directly bind to the promoter of PCAT29 and leads to the suppression of gene expression.

**PCAT29 regulates oncogenic phenotypes in vitro and in vivo**

The androgen receptor drives oncogenesis in treatment-naïve prostate cancer as well as disease progression in castration-resistant prostate cancers. Because androgen receptor binds to the PCAT29 promoter and regulates gene expression, we investigated the functional role of PCAT29. Two independent shRNAs were designed to knockdown the expression of PCAT29 in cells (Supplementary Fig. S3A and S3B). VCaP and LNCaP cells were transfected with PCAT29 shRNAs following analysis using gene expression microarray. We found GO concepts enriched for cell cycle, proliferation, and migration-related genes, suggesting a role of PCAT29 in proliferation and migration (Supplementary Fig. S3D–S3G). Next, we defined a signature of genes positively and negatively correlated with PCAT29 expression from prostate cancer samples as described before (7). We checked the overlap of these genes with the top 1500 differentially expressed genes in PCAT29 knockdown samples of VCAP and LNCAP cells. As expected, the positively correlated genes show a significant overlap with genes downregulated with knockdown of PCAT29 and the negatively correlated genes show a significant overlap with genes upregulated by knockdown of PCAT29 in both VCAP and LNCAP (P < 0.001 for all pairwise comparisons of overlapping genes, Supplementary Fig. S4A–S4D). For overlapping genes, we did see enrichment in pathways such as cell cycle, apoptosis, and cell growth (Supplementary Fig. S4A–S4D). Taken together, this analysis suggested a role of PCAT29 in cell proliferation and migration.

To experimentally validate this observation, cell proliferation was assessed in LNCaP cells transfected with control versus PCAT29 shRNAs. To our surprise, knockdown of PCAT29 in LNCaP cells led to an increase in cell proliferation and migration (Fig. 3A). To further validate this observation, we stably overexpressed the 2 most prevalent isoforms of PCAT29 in DU145 prostate cancer cells using a lentiviral vector (Supplementary Fig. S3C). Consistent with the previous knockdown studies, overexpression of these 2 isoforms of PCAT29 in DU145 led to suppression of cell proliferation and migration (Fig. 3B). We next assessed whether similar effects of PCAT29 could be achieved in vivo. 22RV1 prostate cancer cells overexpressing PCAT29 (isoform-1) were implanted on the CAM of a chicken egg. Compared with control cells, overexpression of PCAT29 significantly decreased the growth of tumor on the CAM as well as decreased liver metastases (Fig. 3C).

Finally, we measured the expression of PCAT29 in an independent cohort of 51 radical prostatectomy specimens from patients with prostate cancer with localized disease and clinical follow-up. As shown in Kaplan–Meier analysis (Fig. 3D), patients with lower PCAT29 expression had significantly higher rates of biochemical recurrence, consistent with our in vitro and in vivo findings.

**Discussion**

In this study, we characterize the novel lncRNA PCAT29. Our findings demonstrate that PCAT29 is directly regulated by the androgen receptor, which binds to the promoter of PCAT29 and suppresses its transcription. *In vitro* studies show that PCAT29 negatively regulates prostate cancer proliferation and migration, and *in vivo* studies demonstrate that PCAT29 inhibits tumor growth and metastases. Low expression of PCAT29 is associated with higher rates of biochemical recurrence, suggesting that PCAT29 represses oncogenic phenotypes via a tumor-suppressive role. While previous studies have nominated and characterized lncRNAs that are dysregulated in cancer (3, 14), the majority of characterized lncRNAs, to date, has been associated with oncogenic roles instead of tumor suppressor functions. In fact, there have been only a handful of lncRNAs identified to date that function in repression of cancer phenotypes, and, to our knowledge, none of these are targets downregulated by known onco genes (14). A recent study identifies a protein-coding gene, CCN3/NOV, as a tumor suppressor that is repressed by androgen receptor (15). Thus, our study represents the first identification of an androgen receptor–repressed lncRNA functioning as a tumor suppressor. While further studies will be required to identify the mechanism of PCAT29 and other tumor suppressor lncRNAs, it is clear that these lncRNAs represent an intriguing area for exploration in cancer biology.

In the context of prostate cancer, androgen-regulated lncRNAs are of fundamental importance, given that all stages of prostate cancer are exquisitely dependent on androgen receptor signaling for growth and survival. Because the majority of clinically relevant prostate cancer therapies target the androgen receptor, our studies would suggest that inhibition of androgen signaling will result in reactivation of PCAT29, providing another mechanism underlying the effectiveness of androgen deprivation therapy.

Clinically, there is a clear need for identification of prognostic biomarkers in prostate cancer to help guide decisions on treatment intensification. The association of high PCAT29 expression with good clinical prognosis and
preclinical suppression of cell proliferation and tumor metastases suggests that decreased expression or loss of PCAT29 may identify subsets of patients who may require further intensification of therapy. As our clinical cohort was composed of hormone-sensitive disease from patients with prostatectomy, further studies need to be performed to determine whether PCAT29 can also serve as a prognostic biomarker in the context of more advanced, castration-resistant disease. Regardless, this study highlights the importance of IncRNAs in prostate cancer biology and prognosis and suggests the need for further research in this relatively unexplored area.

Disclosure of Potential Conflicts of Interest

J.R. Prensner has ownership interest as a co-inventor on prostate cancer ncRNA patent licensed to GenomeDX Biosciences Inc., including PCATs in prostate cancer. M. Iyer has ownership interest in a patent (ncRNA and uses thereof). A.M. Chinnaian is a consultant/advisory board member for Widergen Inc. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: R. Malik, D.R. Robinson, F.Y. Feng, A.M. Chinnaian
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): R. Malik, L. Patel, J.R. Prensner, S. Han, M. Liu, I.A. Asangani, X. Jing, X. Cao, S.M. Dhanasekaran, D.R. Robinson, F.Y. Feng
Writing, review, and/or revision of the manuscript: R. Malik, J.R. Prensner, D.R. Robinson, F.Y. Feng, A.M. Chinnaian
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): M.K. Iyer, T. Ma, X. Jing, X. Cao, D.R. Robinson, F.Y. Feng
Study supervision: R. Malik, D.R. Robinson, F.Y. Feng, A.M. Chinnaian

Acknowledgments

The authors thank Xia Jiang and Vishal Kothari for helpful discussions and technical assistance, as well as Karen Giles for her review of the manuscript and submission of documents. They also thank the University of Michigan Viral vector facility for technical assistance, as well as Karen Giles for her review of the manuscript and submission of documents. They also thank the University of Michigan Viral vector facility for generating the lentiviral constructs.

Grant Support

This work was supported in part by the NIH Prostate Specialized Program of Research Excellence Grant P50CA69568, the Early Detection Research Network grant U01 CA111275, the U.S. NIH R01CA132874-01A1, and the Department of Defense grant PC100171 (A.M. Chinnaian). A.M. Chinnaian is supported by the Doris Duke Charitable Foundation Clinical Scientist Award, the Prostate Cancer Foundation, and the Howard Hughes Medical Institute. A.M. Chinnaian is an American Cancer Society Research Professor and a Taubman Scholar of the
PCAT29 Inhibits Oncogenic Phenotypes in Prostate Cancer

University of Michigan. F.Y. Feng was supported by the Prostate Cancer Foundation and the Department of Defense grant PC094231. R. Malik and J.R. Prensner were supported by the Prostate Cancer Foundation Young Investigator Award. R. Malik was supported by the Department of Defense Postdoctoral Fellowship W81XWH-13-1-0284. A. Sahu was supported by the NIH Predoctoral Fellowship 1F30CA180376-01. M. Iyer was supported by the Department of Defense Predoctoral Fellowship BC100238.

Received May 8, 2014; revised June 17, 2014; accepted June 26, 2014; published OnlineFirst July 16, 2014.

References

The IncRNA PCAT29 Inhibits Oncogenic Phenotypes in Prostate Cancer


Updated version: Access the most recent version of this article at:
doi:10.1158/1541-7786.MCR-14-0257

Supplementary Material: Access the most recent supplemental material at:
http://mcr.aacrjournals.org/content/suppl/2014/07/19/1541-7786.MCR-14-0257.DC1

Visual Overview: A diagrammatic summary of the major findings and biological implications:
http://mcr.aacrjournals.org/content/12/8/1081/F1.expansion.html

Cited articles: This article cites 15 articles, 4 of which you can access for free at:
http://mcr.aacrjournals.org/content/12/8/1081.full.html#ref-list-1

Citing articles: This article has been cited by 2 HighWire-hosted articles. Access the articles at:
/content/12/8/1081.full.html#related-urls

E-mail alerts: Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions: To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions: To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.